Results 81 to 90 of about 14,957,077 (381)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

Nature Medicine, 2022
Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited.
C. Qi, J. Gong, Jian Li, Dan Liu, Yanru Qin, S. Ge, Miao Zhang, Zhi Peng, Jun Zhou, Yanshuo Cao, Xiaotian Zhang, Zhihao Lu, Ming Lu, Jiajia Yuan, Zhenghang Wang, Yakun Wang, Xiaohui Peng, Huiping Gao, Zhen Liu, Huamao Wang, Daijing Yuan, J. Xiao, Hong-jie Ma, Wei Wang, Zonghai Li, Lin Shen   +25 more
semanticscholar   +1 more source

Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. [PDF]

, 2018
One major hurdle to the success of adoptive T-cell therapy is the identification of antigens that permit effective targeting of tumors in the absence of toxicities to essential organs.
Abraham, Tara S., Baybutt, Trevor R., Flickinger, John C., Hersperger, Adam R., Magee, Michael S., Marszalowicz, Glen P, Prajapati, Priyanka, Ridge, Natalie A., Snook, Adam E., Waldman, Scott A.   +9 more
core   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade

Scientific Reports
Previously, we demonstrated that natural host-defence peptide caerin 1.1/caerin 1.9 (F1/F3) increases the efficacy of anti-PD-1 and therapeutic vaccine, in a HPV16 + TC-1 tumour model, but the anti-tumor mechanism of F1/F3 is still unclear. In this study,
Junjie Li, Yuandong Luo, Quanlan Fu, Shuxian Tang, Pingping Zhang, Ian H. Frazer, Xiaosong Liu, Tianfang Wang, Guoying Ni   +8 more
doaj   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy. [PDF]

, 2020
Bryostatin 1 is a marine natural product under investigation for HIV/AIDS eradication, the treatment of neurological disorders, and enhanced CAR T/NK cell immunotherapy.
Hardman, Clayton, Ho, Stephen, Luu-Nguyen, Quang, Marsden, Matthew D, Shimizu, Akira, Sloane, Jack L, Soliman, Mohamed SA, Wender, Paul A, Zack, Jerome A   +8 more
core  

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies

Molecular Cancer, 2020
Targeting T cell receptor β-chain constant region 1 (TRBC1) CAR-T could specifically kill TRBC1+ T-cell malignancies. However, over-expressed CARs on anti-TRBC1 CAR transduced TRBC1+ T cells (CAR-C1) bound to autologous TRBC1, masking TRBC1 from ...
Chaoting Zhang, Heyilimu Palashati, Zhuona Rong, Ningjing Lin, Luyan Shen, Ying Liu, Shance Li, Bentong Yu, Wenjun Yang, Zheming Lu   +9 more
doaj   +1 more source

Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells

Journal of Hematology & Oncology, 2022
Persistence of CAR-T cell function is associated with relapse rate after CAR-T therapy, while co-stimulatory agents are highly concerned with the persistence of CAR-T cells.
Jingwen Tan, Yujie Jia, Meixia Zhou, Chengcheng Fu, Israth Jahan Tuhin, Jing Ye, Masuma Akter Monty, Nan Xu, Liqing Kang, Minghao Li, Jiaqi Shao, Xiaoyan Fang, Hongjia Zhu, Lingzhi Yan, Changju Qu, Shengli Xue, Zhengming Jin, Suning Chen, Haiwen Huang, Yang Xu, Jia Chen, Miao Miao, Xiaowen Tang, Caixia Li, Zhiqiang Yan, Depei Wu, Lei Yu   +26 more
doaj   +1 more source

Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma [PDF]

, 2019
Almost all multiple myeloma (MM) cases have been demonstrated to be linked to earlier monoclonal gammopathy of undetermined significance (MGUS). Nevertheless, there are no identified characteristics in the diagnosis of MGUS that have been helpful in ...
Allegra A., Allegra A. G., Di Salvo E., Gangemi S., Innao V., Musolino C., Pugliese M., Ventura-Spagnolo E.   +7 more
core   +1 more source